IRLAB prepares for listing on the Nasdaq Stockholm main market
IRLAB Therapeutics AB’s board of directors has resolved to evaluate listing the company’s shares on Nasdaq Stockholm’s main market.
Since February 28, 2017, IRLAB’s shares trade on Nasdaq Stockholm First North Premier. The board considers that a listing on the main market will enhance the company’s development opportunity.
For further information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
This information is information that IRLAB Therapeutics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:45 CET on May 17, 2018.
FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North Premier.
IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.
IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson’s disease. IRLAB also has additional programs in pre-clinical stages.
IRLAB’s research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.
IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.
For more information, please visit www.irlab.se.